British biotech company Circassia Pharmaceuticals sank on Monday after its experimental cat allergy treatment failed in a late-stage trial. The company lost almost two -thirds of its value. Its two biggest shareholders are Invesco and Neil Woodford, who have increased their holdings in the last six months to 35.1 and 19.2 percent respectively, according to … Continue reading “Cat Allergy Sent This Pharma Company Plummeting”